



STUDY OF SERUM LIPID PROFILE, LIPID RATIOS IN CHRONIC KIDNEY DISEASE(CKD) PATIENTS IN CHITTOOR

Biochemistry

Chand Basha Sk Y*

Assistant Professor, Department of Biochemistry, Apollo institute of Medical Sciences and Research, Chittoor. *Corresponding Author

Banubadi Anil Kishore

Assistant Professor, Department of Biochemistry, Apollo institute of Medical Sciences and Research, Chittoor.

ABSTRACT

Cardiovascular disease is the leading cause of hospitalization and mortality in patients with chronic kidney. The rapid decline in renal function and the commencement of renal replacement therapy in CKD patients is associated with Dyslipidaemia. 120 subjects were taken in the study. The chief finding of the current study was that the Triglycerides was associated with an increased risk of CKD in men. Though, in women, none of the serum lipids and lipid ratios was associated with CKD. TG and TG/HDL-C ratio correlated negatively with eGFR in both genders.

KEYWORDS

Chronic Kidney Disease, Dyslipidemia, HDL, LDL, Cardiovascular Disease, Lipid Ratios,

INTRODUCTION:

One of the important cardiovascular risk factors responsible for cardiovascular disease and the rapid progression of chronic kidney disease (CKD) to end-stage renal disease is Dyslipidaemia. An important aspect of the reduction of cardiovascular complications and retardation of the progression of CKD is early detection and management of dyslipidemia. The leading cause of hospitalization and mortality in patients with chronic kidney disease is Cardiovascular complications¹. The process of cardiovascular disease most likely starts in the early stages of CKD when its severity is considered at commencement of (RRT).² A rapid decline in renal function and commencement of renal replacement therapy in CKD patients is associated with Dyslipidaemia.^{8,9} The precise mechanism is unknown, but it has been postulated theory says that mesangial cells bind and then take up oxidized LDL which later causes injury to mesangial, epithelial and endothelial cells by supporting enlistment of inflammatory cells such as macrophages which cause cytokines, chemokines and growth factors release^{10,11}. This consequently leads to glomerulosclerosis¹⁰. Podocyte injury and mesangial sclerosis are also seen which are due to Hypercholesterolaemia and hypertriglyceridemia, afterward leading to glomerulosclerosis. Elevated triglyceride (TG), elevated total cholesterol (TC), (LDL-C) and reduced high-density lipoprotein cholesterol are characters of Dyslipidaemia in CKD patients (HDL-C).^{5,7} Dyslipidaemia being a modifiable cardiovascular risk factor, can be managed with early diagnosis, lifestyle modification, and lipid-lowering medications which in turn will reduce cardiovascular disease risk and progression of CKD to end-stage renal disease (ESRD). It has been reported that statins used for Treatment of dyslipidemia reduce the rate of decline in glomerular filtration rate (GFR) in CKD patients¹³. This study was done to work out the prevalence and pattern of dyslipidemia in relevance age, gender, and severity of CKD among pre-dialysis CKD patients.

MATERIALS AND METHODS:

60 consecutive pre-dialysis CKD patients that fulfilled criteria for the study and 60 age and sex-matched controls are taken. Inclusion criteria for CKD subjects are adults patients with CKD stages 1-5 yet to commence dialysis. Those who had a renal transplant and those on dietary restriction, lipid-lowering medications, steroids, or immunosuppressants are excluded from the study. Inclusion criteria for control subjects were adults aged ≥ 18 years who are neither hypertensive nor diabetic with normal renal function, females who

are not pregnant and not on steroids, immunosuppressant, or lipid-lowering medications. Patients are interviewed, examined for renal disease. Weight and height were measured. Body mass index (kg/m^2) is calculated using the formula $[\text{Weight (kg)}/\text{Height (m)}^2]$. Fasting venous blood is obtained from patients to perform biochemical tests which included serum creatinine and fasting serum lipids. Total serum cholesterol and triglycerides are determined by enzymatic estimation,¹⁶ while HDL-C was determined by precipitation¹⁷. LDL-C is estimated using Friedwald formula.¹⁸

Glomerular filtration rate is estimated using the Cockcroft Gault formula

$$\text{CCr} = \{((140 - \text{age}) \times \text{weight}) / (72 \times \text{SCr})\} \times 0.85 \text{ (if female)}$$

Definition Of Variables

Obesity is defined as $\text{BMI} > 29.9 \text{ kg}/\text{m}^2$.

STAGES OF CKD:

- stage 1 (GFR ≥ 90 ml/min with evidence of kidney damage),
- stage 2 (GFR 60-89 ml/min with evidence of kidney damage),
- stage 3 (GFR = 30-59 ml/min with or without evidence of kidney damage),
- stage 4 (GFR = 15-29 ml/min with or without evidence of kidney damage)
- stage 5 (GFR < 15 ml/min with or without evidence of kidney damage).²¹

Dyslipidaemia is defined as any or a combination of the following:

TC > 200 mg/dl, HDL-C < 50 mg/dl in females and < 40 mg/dl in males, LDL-C > 135 mg/dl and TG > 150 mg/dl.²²

P value < 0.05 was taken as statistically significant. We used mean $\pm$ standard deviation to describe continuous variables with a normal distribution and medians and interquartile ranges for skewed distributed variables. Frequencies and percentages were used to indicate categorical variables. The clinical characteristics of the study population were listed. We also compared the characteristics of male and female subjects. Student's T test or rank-sum test was used for continuous variables and the chi-squared test for categorical variables.

RESULTS:

Table 1: Clinical Characteristics Of Male And Female Subjects.

CLINICAL CHARACTERISTICS	Total (n=120)	Male (n=45)	Female (n=75)	Pvalue
Age(Years)	50 $\pm$ 13	50 $\pm$ 13	50 $\pm$ 14	0.29
Waist circumference(cm)	83 $\pm$ 10	86 $\pm$ 10	81 $\pm$ 10	< 0.001
History of Hypertension(%)	372(20.28)	166(24.45)	206(17.84)	0.001
History of Diabetes(%)	115(6.27)	48(7.07)	67(5.80)	0.29
History of Coronary heart disease(%)	42(2.29)	23(3.39)	19(1.65)	0.27
Physical inactivity(%)	1013(55.23)	374(55.08)	639(55.32)	< 0.001
Systolic blood pressure(mmHg)	129 $\pm$ 20	130 $\pm$ 19	127 $\pm$ 21	0.003




Fig 1: Clinical Characteristics Of Male And Female Subjects

Table 2: Other Laboratory Findings

OTHER LABORATORY FINDINGS	Total (n=120)	Male (n=45)	Female (n=75)	Pvalue
Serum creatinine (mg/dl)	0.8±0.14	0.9±0.16	0.7±0.12	<0.001




FIG 2,3: Other Laboratory Findings

Table 3: Serum Lipid Values In Males And Females

SERUM LIPIDS	Total (n=120)	Male (n=45)	Female (n=75)	Pvalue
Cholesterol (mg/dl)	215±56	219±53	220±58	0.09
LDL (mg/dL)	115±23	116±20	117±18	0.19
HDL (mg/dl)	55±8	52±7	56±8	<0.001
Triglycerides (mg/dl)	149±23	157±15	152±19	<0.001
LDL/HDL ratio	2.09(1.67–2.59)	2.23(1.81–2.76)	2.08(1.60–2.48)	<0.001
TG/HDL ratio	2.76(1.35–2.84)	3.01(1.68–3.25)	2.71(1.17–2.86)	<0.001
TC/HDL ratio	3.90(3.01–4.15)	4.21(3.23–4.38)	3.92(2.92–4.05)	<0.001
Dyslipidemia	1474(80.37)	556(81.89)	918(79.48)	0.21




FIG 4,5 Serum Lipids And Lipid Ratios




FIG 6 Dyslipidemias In Males And Females

TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; eGFR: Estimated glomerular filtration rate; ACR: Urinary albumin to creatinine ratio; CKD: chronic kidney disease.

A total of 120 subjects (the mean age was 50 ± 13 years) were included in the analysis.

Men had a significantly larger waist circumference, a higher SBP, and a higher DBP than women. Women had a higher level of eGFR than men, but there was no significant difference in the prevalence of CKD between men and women. In the past three months, no subjects used contrast agents or antibiotics. The proportions of current smokers and current alcohol use were significantly higher in men.

Men had a higher TG/HDL-C ratio, a higher TC/HDL-C ratio, and a

higher LDL-C/HDL-C ratio than women and all of these differences were significant ($P < 0.05$). Men also had higher serum TGs and lower HDL-Cs than women.

DISCUSSION:

The chief finding of the current study was that the Triglycerides was associated with an increased risk of CKD in men. Though, in women, none of the serum lipids and lipid ratios was associated with CKD.

TG and TG/HDL-C ratio was negatively correlated with eGFR in both genders. In women, the serum lipids and lipid ratios didn't correlate with albuminuria.

Many previous studies have shown that an important role in the pathogenesis and progression of kidney disease is played by both a high level of cholesterol and triglyceride^{23,24}. Hypercholesterolemia inducing a pro-inflammatory response and resulting in macrophages recruitment was found in many rat models²⁵. Both hyperlipidemia and macrophage inflow appear to lead to the beginning of glomerulosclerosis.

It appears that food restriction can preclude hypertriglyceridemia induced glomerular injury and macrophage influx observed in obese Zucker rats. Many of these studies have indicated that dyslipidemia can add to kidney damage. Dyslipidemia is also an independent risk factor for the evolution of kidney disease in patients with diabetes.

Samuelsson et al.'s study²⁶ indicated that TC, LDL-C, and triglyceride-rich apoB-containing lipoproteins contributed to a more rapid decline in renal function when 73 non-diabetic patients with CKD were followed for an average of 3.2 years. It was shown that hypertriglyceridemia and low HDL-C were associated with the incidence of CKD, where the models were only adjusted for variables like age, gender, and race in the Atherosclerosis Risk in Communities study after 9 years' follow-up.

In the present study, the incidence of CKD in men was associated with TG, but CKD in women was not associated with all of the serum lipids and lipid ratios.

Kim et al. predicted CKD in Korean populations using lipid ratios.

The results showed that CKD in both men and women is associated with an altered TG/HDL-C ratio.

However, in the present study, there is no significant association of lipid ratios with CKD in the population. Though hyperlipidemia and hypercholesterolemia are independent risk factors for the progression of kidney disease, there is no conclusive evidence that demonstrates that isolated hyperlipidemia can lead to CKD in healthy individuals. Hyperlipidemia can be accompanied by coronary heart disease, diabetes, and hypertension.

Some results support lipid-lowering therapy in patients with CKD, diabetes, and coronary heart disease.

CONCLUSION:

In the present study, both TG and TG/HDL-C ratio negatively correlated with eGFR in both genders.

There are several limitations of the current study that need to be acknowledged.

Firstly, this is only a cross-sectional study. There might be increased atherogenicity of LDL-C related to heavy proteinuria or end-stage renal disease according to previous studies.

Secondly, albuminuria and eGFR were not measured repeatedly.

Thirdly, individuals who were included were those who responded to an invitation, this might lead to a selection bias. Participation willingness might be higher in those individuals having more comorbidity.

STATEMENT OF FUNDING: No funding has been received for doing this study.

CONTRIBUTION OF AUTHORS:

STATEMENT OF CONFLICT: I/We (Authors) have no conflict of interest.

ETHICS STATEMENT:

This study was approved by the Institutional ethics committee of the Apollo Institute Of Medical Sciences And Research Chittoor, Apollo Medical College. Written informed consent was obtained from all subjects.

REFERENCES:

1. Rayner HC, Pisoni RL, Bommer J, Canaud B, Hecking E, Locatelli F et al. Mortality and Hospitalization in haemodialysis in five European countries. Results from dialysis outcome and practice patterns study (DOPPS). *Nephrol Dial Transplant* 2004; 19:108-120.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical and echocardiographic disease in patients starting end stage renal disease therapy. *Kidney Int* 1995;47(1):186-192
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with MI in 52 countries (The INTERHEART Study): case-control study *Lancet* 2004;364(9438):937-952
4. Locatelli F, Pozzoni P, Tentori F, Vecchio L D. Epidemiology of cardiovascular risk in patients with chronic kidney disease. *Nephrol Dial Transplant* 2003 ;18(7):2-9
5. Akpan EE, Ekrikpo UE, Effa EE, Udo AA, Kadiri S. Assessment of dyslipidemia in pre-dialysis patients in south-west Nigeria. *Niger Med J* 2014;55(3):214-9
6. Chijioke A, Makusidi AM, Shittu OA, Sanni MA, Bilaminu SA, Abdul-Rahman S et al. Pattern of lipid profile in dialysis naïve patients from Ilorin, Nigeria. *Internet J Nephrol* 2011; 6(1):1-7.
7. Mshelia DS, Brutai LB, Mamza YP. Lipid profile in predialysis patients chronic kidney disease patients attending University of Maiduguri Teaching Hospital, Nigeria. *Niger J Clin Pract* 2002;12(2):173-178.
8. Chen SC, Hung CC, Kuo MC, Lee JJ, Chiu YW, Chang J et al. Association of Dyslipidemia with Renal Outcomes in Chronic Kidney Disease. *PLoS ONE* 2013 8(2): e55643 doi:10.1371/journal.pone.0055643
9. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. *Kidney Int* 2001;59:260-269
10. Schlondorff D. Cellular mechanisms of lipid injury in the glomerulus. *Am J Kidney Dis.* 1993;22(1):72-82
11. Guijario C, Kasiske BL, Kuin Y, O'Donnell MP, Lee HS, Keane WF. Early glomerular changes in rats with dietary-induced hypercholesterolemia. *Am J Kidney Dis* 1995;26(1):152-161.
12. Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities Study. *J Am Soc Nephrol* 2005;16(2):529-538
13. Athobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH. The effect of statins on urinary albumin excretion and glomerular filtration rate: Results from both a randomized clinical trial and an observational cohort study. *Nephrol Dial Transplant* 2006;21(11): 3106-3114.
14. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York, NY: John Wiley & Sons; 1981
15. Okaka EI, Eiya BO. Prevalence and pattern of dyslipidaemia in a rural community in southern Nigeria. *Afr J Med Health Sci* 2013;12:82-86

16. Timothy P, Catherine JA, Lawrence LR. Enzymatic determination of triglycerides free cholesterol and total cholesterol in tissue lipid extracts. *Clinical Biochemistry* 1993;26(1):36-42
17. Ononogbu IC, Lewis B. Lipoprotein fractionation by a precipitation method; a simple quantitative procedure. *Clinica Chimica Acta* 1996; 71(3):397-402
18. Naoto F, Kazuhiko H, Noriaki W, Koari K, Asako S, Hikari O et al. Validation of Friedewald equation for evaluation of plasma LDL-cholesterol. *J Clin Biochem Nutri* 2008; 43(1):1-5
19. Abefe SA, Abiola AF, Olubunmi AA, Adewale A. Utility of predicted creatinine clearance using MDRD formula compared with other predictive formulas in Nigerian patients. *Saudi J Kidney Dis Transpl* 2009; 20(1):86-90.
20. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults - The evidence report. National Institutes of Health. *Obes Res* 1998;6 (Suppl 2):51-209
21. KDIGO 2012 Clinical Practice Guideline of evaluation and management of CKD. *Kidney Int Suppl* 2013;3(1):1-150.
22. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285(19):2486.
23. Wheeler D.C., Fernando R.L., Gillett M.P., Zaruba J., Persaud J., Kingstone D., Varghese Z., Moorhead J.F. Characterisation of the binding of low-density lipoproteins to cultured rat mesangial cells. *Nephrol. Dial. Transpl.* 1991;6:701-708. doi: 10.1093/ndt/6.10.701. [PubMed] [CrossRef] [Google Scholar]
24. Al-Shebeb T., Frohlich J., Magil A.B. Glomerular disease in hypercholesterolemic guinea pigs: A pathogenetic study. *Kidney Int.* 1988;33:498-507. doi: 10.1038/ki.1988.26. [PubMed] [CrossRef] [Google Scholar]
25. Neverov N.I., Kaysen G.A., Nuccitelli R., Weiss R.H. HDL causes mesangial cell mitogenesis through a tyrosine kinase-dependent receptor mechanism. *J. Am. Soc. Nephrol.* 1997;8:1247-1256. [PubMed] [Google Scholar]
26. Samuelsson O., Attman P.O., Knight-Gibson C., Larsson R., Mulec H., Weiss L., Alaupovic P. Complex apolipoprotein B-containing lipoprotein particles are associated with a higher rate of progression of human chronic renal insufficiency. *J. Am. Soc. Nephrol.* 1998;9:1482-1488. [PubMed] [Google Scholar]